Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
Authors
Keywords
-
Journal
Future Oncology
Volume 7, Issue 2, Pages 263-283
Publisher
Future Medicine Ltd
Online
2011-02-24
DOI
10.2217/fon.11.2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy
- (2017) P. N. Munster et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
- (2010) O. Goodyear et al. BLOOD
- Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells
- (2010) Hyun Chang et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
- (2010) U Lassen et al. BRITISH JOURNAL OF CANCER
- A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
- (2010) Dana Rathkopf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage
- (2010) Chiara Conti et al. CANCER RESEARCH
- Elevated NCOR1 disrupts PPARα/γ signaling in prostate cancer and forms a targetable epigenetic lesion
- (2010) Sebastiano Battaglia et al. CARCINOGENESIS
- Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments
- (2010) Fabrício F T Barros et al. HISTOPATHOLOGY
- Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells
- (2010) Hyun Chang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines
- (2010) Bhaswati Sarcar et al. JOURNAL OF NEURO-ONCOLOGY
- HDAC Inhibitor-Mediated Radiosensitization in Human Carcinoma Cells: A General Phenomenon?
- (2010) In Ah KIM et al. JOURNAL OF RADIATION RESEARCH
- Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
- (2010) Anne Hansen Ree et al. LANCET ONCOLOGY
- Chemical phylogenetics of histone deacetylases
- (2010) James E Bradner et al. Nature Chemical Biology
- EGFR Signaling and Drug Discovery
- (2010) Georg Lurje et al. ONCOLOGY
- Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor
- (2010) Sushant K. Kachhap et al. PLoS One
- Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
- (2010) J.- H. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer
- (2010) Minja J. Pfeiffer et al. PROSTATE
- ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)
- (2009) S. E. Witta et al. ANNALS OF ONCOLOGY
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- HDAC inhibitor-based therapies and haematological malignancy
- (2009) L. Stimson et al. ANNALS OF ONCOLOGY
- Sirtuins inhibitors: The approach to affinity and selectivity
- (2009) Yana Cen BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
- (2009) M. E. Figueroa et al. BLOOD
- Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
- (2009) P N Munster et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
- (2009) D. S. Welsbie et al. CANCER RESEARCH
- A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
- (2009) J. Lin et al. CLINICAL CANCER RESEARCH
- Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma
- (2009) G. Lopez et al. CLINICAL CANCER RESEARCH
- Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
- (2009) M. T. Voso et al. CLINICAL CANCER RESEARCH
- Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
- (2009) A. I. Daud et al. CLINICAL CANCER RESEARCH
- Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
- (2009) P. Munster et al. CLINICAL CANCER RESEARCH
- Successful Treatment of Anaplastic Thyroid Carcinoma with a Combination of Oral Valproic Acid, Chemotherapy, Radiation and Surgery
- (2009) Hitoshi NOGUCHI et al. ENDOCRINE JOURNAL
- Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells
- (2009) Taofeek K. Owonikoko et al. INTERNATIONAL JOURNAL OF CANCER
- Radiosensitization by SAHA in Experimental Colorectal Carcinoma Models—In Vivo Effects and Relevance of Histone Acetylation Status
- (2009) Sigurd Folkvord et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
- (2009) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat in solid and hematologic malignancies
- (2009) David Siegel et al. Journal of Hematology & Oncology
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts
- (2009) A. Baschnagel et al. MOLECULAR CANCER THERAPEUTICS
- HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
- (2009) D. C. Marchion et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis
- (2009) F. Bruzzese et al. MOLECULAR CANCER THERAPEUTICS
- Genetic dissection of histone deacetylase requirement in tumor cells
- (2009) M. Haberland et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
- (2008) W Weichert et al. BRITISH JOURNAL OF CANCER
- Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor-Mediated Signaling
- (2008) E. Bicaku et al. CANCER RESEARCH
- A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma
- (2008) M.D. Shelley et al. CANCER TREATMENT REVIEWS
- Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
- (2008) G. Zhang et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
- Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
- (2008) F. Braiteh et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
- (2008) I. Oehme et al. CLINICAL CANCER RESEARCH
- Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer
- (2008) Mari Björkman et al. INTERNATIONAL JOURNAL OF CANCER
- ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor
- (2008) Jiang Fan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
- (2008) Kyunghee Burkitt et al. Molecular Cancer
- DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes
- (2008) Elizabeth A. Griffiths et al. SEMINARS IN HEMATOLOGY
- Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas
- (2008) Omar Khan et al. Nature clinical practice. Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started